Htr1B Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute | Value |
|---|---|
| Protein Name | Serotonin Receptor 1B |
| Gene Symbol | htr1b |
| UniProt ID | P28222 |
| Molecular Weight | ~43-50 kDa |
| Subcellular Localization | Plasma membrane, presynaptic terminals |
| Protein Family | 5-HT1 family (GPCR) |
| Signal Transduction | Gi/o protein-coupled, inhibits adenylate cyclase |
The Serotonin Receptor 1B (HTR1B) is a G protein-coupled receptor encoded by the HTR1B gene. It functions as both an autoreceptor (regulating serotonin release) and heteroreceptor (modulating release of other neurotransmitters). HTR1B is a key target for migraine medications, antidepressants, and drugs for substance abuse.
HTR1B exhibits the classic seven-transmembrane GPCR architecture:
The receptor has high affinity for serotonin (5-HT) and is sensitive to tryptamine derivatives.
HTR1B serves critical regulatory functions:
HTR1B is the primary target for triptans (sumatriptan, zolmitriptan, rizatriptan), which are acute migraine abortives. These drugs act as HTR1B (and HTR1D) agonists to cause cranial vasoconstriction and inhibit trigeminal nociception.
HTR1B alterations affect serotonin-dopamine interactions in basal ganglia. Altered receptor density has been reported in PD brains, contributing to non-motor symptoms including depression and anxiety.
HTR1B signaling modulates amyloid precursor protein processing. Animal studies suggest HTR1B agonists may reduce Aβ production, though human data are limited.
HTR1B is implicated in mood disorders through its role in serotonin autoreceptor function. Chronic SSRI treatment leads to HTR1B desensitization, enhancing antidepressant efficacy.
| Drug Class | Examples | Mechanism | Status |
|---|---|---|---|
| Triptans | Sumatriptan, Zolmitriptan | HTR1B/1D agonists | FDA approved for migraine |
| Antidepressants | SSRIs (indirect) | Downregulate HTR1B | FDA approved |
| Research Compounds | CP-93,129, Isohexenyl | Selective agonists/antagonists | Preclinical |
The study of Htr1B Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Hoyer D, et al. (1985). Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites. European Journal of Pharmacology. PMID:2995204
[2] Barnes NM, et al. (1988). Serotonin receptor subtypes. Neuropsychopharmacology. PMID:2907428
[3] Goa K, et al. (1996). Sumatriptan. A review of its pharmacodynamic properties. Drugs. PMID:8785319
[4] Sari Y, et al. (2004). Serotonin1B receptor modulation of dopamine release. Progress in Neuropsychopharmacology. PMID:15026168
[5] Saudou F, et al. (1994). Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science. PMID:8235615